Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%
Pfizer hit some unexpected roadblocks with its first U.S. biosimilar launch, but it’s not giving up in the budding field. Now, the drugmaker is launching biosims to three Roche cancer blockbusters at discounts ranging from 22% to 24%. The company has already rolled out Zirabev and Ruxience, its biosimilars to Roche’s Avastin and Rituxan, respectively, at discounts of 23% and 24%. On… Read More »